JAZZ Jazz Pharmaceuticals plc
Price (delayed)
$136.01
Market cap
$8.22B
P/E Ratio
18.26
Dividend/share
N/A
EPS
$7.45
Enterprise value
$12.19B
Jazz Pharmaceuticals plc is a biopharmaceutical company based in Ireland. It was founded in 2003. One of the company's most significant products is the United States Food and Drug Administration
Highlights
Jazz Pharmaceuticals's quick ratio has soared by 130% YoY and by 88% from the previous quarter
Jazz Pharmaceuticals's equity has increased by 20% YoY and by 11% from the previous quarter
The company's debt rose by 7% QoQ and by 7% YoY
Key stats
What are the main financial stats of JAZZ
Market
Valuations
Earnings
Shares outstanding
60.45M
Market cap
$8.22B
Enterprise value
$12.19B
Price to earnings (P/E)
18.26
Price to book (P/B)
2.01
Price to sales (P/S)
2.09
EV/EBIT
18.64
EV/EBITDA
9.34
EV/Sales
3.05
Revenue
$3.99B
Gross profit
$3.57B
Operating income
$648.36M
Net income
$463.16M
EBIT
$653.72M
EBITDA
$1.3B
Free cash flow
$1.13B
Per share
Balance sheet
Liquidity
EPS
$7.45
EPS diluted
$7.11
Free cash flow per share
$18.4
Book value per share
$67.54
Revenue per share
$65.01
TBVPS
$86.41
Total assets
$12.26B
Total liabilities
$8.08B
Debt
$6.18B
Equity
$4.17B
Working capital
$3.36B
Debt to equity
1.48
Current ratio
4.26
Quick ratio
3.24
Net debt/EBITDA
3.04
Margins
Efficiency
Dividend
EBITDA margin
32.7%
Gross margin
89.4%
Net margin
11.6%
Operating margin
16.2%
Return on assets
4%
Return on equity
12.1%
Return on invested capital
8.8%
Return on capital employed
5.8%
Return on sales
16.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
JAZZ stock price
How has the Jazz Pharmaceuticals stock price performed over time
Intraday
-0.47%
1 week
1.53%
1 month
12.01%
1 year
5.91%
YTD
10.44%
QTD
10.44%
Financial performance
How have Jazz Pharmaceuticals's revenue and profit performed over time
Revenue
$3.99B
Gross profit
$3.57B
Operating income
$648.36M
Net income
$463.16M
Gross margin
89.4%
Net margin
11.6%
Jazz Pharmaceuticals's net income has increased by 17% QoQ
The operating income rose by 16% since the previous quarter
The company's net margin rose by 15% QoQ
JAZZ's operating margin is up by 13% since the previous quarter
Growth
What is Jazz Pharmaceuticals's growth rate over time
Valuation
What is Jazz Pharmaceuticals stock price valuation
P/E
18.26
P/B
2.01
P/S
2.09
EV/EBIT
18.64
EV/EBITDA
9.34
EV/Sales
3.05
The company's EPS rose by 19% QoQ
Jazz Pharmaceuticals's equity has increased by 20% YoY and by 11% from the previous quarter
The price to book (P/B) is 13% lower than the 5-year quarterly average of 2.3 but 6% higher than the last 4 quarters average of 1.9
The price to sales (P/S) is 23% less than the 5-year quarterly average of 2.7 but 10% more than the last 4 quarters average of 1.9
The revenue has grown by 5% YoY and by 2.1% from the previous quarter
Efficiency
How efficient is Jazz Pharmaceuticals business performance
The company's return on assets rose by 14% QoQ
The company's return on sales rose by 13% QoQ
The return on equity has increased by 12% since the previous quarter
JAZZ's ROIC is up by 10% QoQ
Dividends
What is JAZZ's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for JAZZ.
Financial health
How did Jazz Pharmaceuticals financials performed over time
The total assets is 52% greater than the total liabilities
Jazz Pharmaceuticals's quick ratio has soared by 130% YoY and by 88% from the previous quarter
The company's current ratio has surged by 107% YoY and by 80% QoQ
The company's debt is 48% higher than its equity
Jazz Pharmaceuticals's equity has increased by 20% YoY and by 11% from the previous quarter
Jazz Pharmaceuticals's debt to equity has decreased by 11% YoY and by 3.3% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.